![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeut... Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. Show more
Halozyme Announces Roche's OCREVUSยฎ SC with ENHANZEยฎ Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis PR Newswire SAN DIEGO, June 25, 2024 OCREVUSยฎ...
Halozyme Announces argenx Receives FDA Approval for VYVGARTยฎ Hytrulo Co-Formulated with ENHANZEยฎ for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire SAN DIEGO, June 21, 2024...
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook PR Newswire SAN DIEGO, June 6, 2024 Company Granted New European Patent for ENHANZEยฎ Drug Delivery Platform...
Halozyme Announces Issuance of New European Patent for ENHANZEยฎ Drug Delivery Platform PR Newswire SAN DIEGO, June 5, 2024 Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am...
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire SAN DIEGO, June 4, 2024 SAN DIEGO, June 4, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.96 | 3.7297811608 | 52.55 | 54.83 | 52.12 | 1511917 | 52.87504612 | CS |
4 | 4.57 | 9.15098117741 | 49.94 | 54.83 | 48.995 | 1428067 | 52.11011301 | CS |
12 | 15.76 | 40.6709677419 | 38.75 | 54.83 | 37.965 | 1253450 | 47.78364368 | CS |
26 | 20.35 | 59.5725995316 | 34.16 | 54.83 | 33.15 | 1215362 | 42.501383 | CS |
52 | 15.77 | 40.7072792979 | 38.74 | 54.83 | 32.83 | 1118417 | 40.88094691 | CS |
156 | 10.72 | 24.4804749943 | 43.79 | 59.46 | 29.85 | 1126056 | 41.57969304 | CS |
260 | 37.62 | 222.735346359 | 16.89 | 59.46 | 12.71 | 1213009 | 35.94614762 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions